E-ISSN 2231-3206 | ISSN 2320-4672
 

Original Research

Online Publishing Date:
13 / 04 / 2024

 


A prospective study of demographic, clinical profile, treatment of necrotizing fasciitis, and its consequences

Vignesh R, Arun Walwekar, Vishwanath G Shettar, Rekha Walwekar.


Abstract
Background: The infection that spreads along the fascial planes and causes widespread necrosis is known as necrotizing fasciitis (NF). An uncommon but potentially deadly infectious disease, NF places a significant financial strain on both individuals and the health-care system. There are four occurrences for every 100,000 person-years. Patients with type 1 (polymicrobial) NF are typically immune-compromised, whereas those with type 2 (monomicrobial) NF are typically immune-competent with a trauma history. Type 1 NF has a death rate of 21%, while Type 2 NF has a death rate of 14–34%. Furthermore, NF has the potential to significantly lower patients’ quality of life, especially for those who are having an amputation. Another significant issue for public health is the high death rate. Patients with advanced age, diabetes, smoking, immunosuppression, obesity, malnutrition, steroid therapy, and HIV are more likely to have the disease. Injury and diabetes are important factors. Only few studies have conducted to correlate demographic and clinical features treatment and its outcomes. Therefore, the study is conducted to correlate demographic and clinical features, treatment of NF, and its outcomes.

Aims and Objectives: The aims of this study were as follows: (1) to study demographic, clinical profile of patients with NF and (2) to analyze the treatment and outcomes of NF.

Materials and Methods: This cohort study was carried out for cases that were clinically diagnosed with NF in patients admitted under the Department of Surgery, Karnataka Institute of Medical Sciences, Hubli, from December 2019 to December 2021. After clearance from the Institutional Ethics Committee, 124 cases were selected based on the inclusion and exclusion criteria.

Results: A total of 124 patients were enrolled and analyzed in this study. Most common age group to be affected was 51–60 years. One hundred were male and 24 were female, with male: female ratio of 4.2: 1. Lower limb 95 (76.61%) was the most common site to be involved. Most common risk/precipitating factor for developing NF is trauma 43 (34.65%) followed by diabetes 40 (32.25%). Most common antibiotic used in this study was piperacillin combined with tazobactum in 53 patients (43.54%). Total 124 patients, among them 25 patients underwent amputation, 33 patients were in septic shock and succumbed due to same, 13 patients ended up in skin grafting, the mean duration of hospital stay was 13.46 days, and mean number of debridement was 1.129.

Conclusion: In this study, mortality was higher (53.23%), but there was a good improvement in all the surviving patients. Early surgical intervention (within 72 h) with broad spectrum antimicrobials has a favorable outcome. Prompt and early surgical intervention with holistic care helps in reducing morbidity and mortality.

Key words: Necrotizing Fasciitis; Demographic; Clinical Profile; Treatment and Consequences


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Vignesh R
Articles by Arun Walwekar
Articles by Vishwanath G Shettar
Articles by Rekha Walwekar
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

R V, Walwekar A, Shettar VG, Walwekar R. A prospective study of demographic, clinical profile, treatment of necrotizing fasciitis, and its consequences. Natl J Physiol Pharm Pharmacol. Online First: 13 Apr, 2024. doi:10.5455/njppp.2024.14.03137202404042024


Web Style

R V, Walwekar A, Shettar VG, Walwekar R. A prospective study of demographic, clinical profile, treatment of necrotizing fasciitis, and its consequences. https://www.njppp.com/?mno=195320 [Access: April 19, 2024]. doi:10.5455/njppp.2024.14.03137202404042024


AMA (American Medical Association) Style

R V, Walwekar A, Shettar VG, Walwekar R. A prospective study of demographic, clinical profile, treatment of necrotizing fasciitis, and its consequences. Natl J Physiol Pharm Pharmacol. Online First: 13 Apr, 2024. doi:10.5455/njppp.2024.14.03137202404042024



Vancouver/ICMJE Style

R V, Walwekar A, Shettar VG, Walwekar R. A prospective study of demographic, clinical profile, treatment of necrotizing fasciitis, and its consequences. Natl J Physiol Pharm Pharmacol, [cited April 19, 2024]; Online First: 13 Apr, 2024. doi:10.5455/njppp.2024.14.03137202404042024



Harvard Style

R, V., Walwekar, . A., Shettar, . V. G. & Walwekar, . R. (2024) A prospective study of demographic, clinical profile, treatment of necrotizing fasciitis, and its consequences. Natl J Physiol Pharm Pharmacol, Online First: 13 Apr, 2024. doi:10.5455/njppp.2024.14.03137202404042024



Turabian Style

R, Vignesh, Arun Walwekar, Vishwanath G Shettar, and Rekha Walwekar. 2024. A prospective study of demographic, clinical profile, treatment of necrotizing fasciitis, and its consequences. National Journal of Physiology, Pharmacy and Pharmacology, Online First: 13 Apr, 2024. doi:10.5455/njppp.2024.14.03137202404042024



Chicago Style

R, Vignesh, Arun Walwekar, Vishwanath G Shettar, and Rekha Walwekar. "A prospective study of demographic, clinical profile, treatment of necrotizing fasciitis, and its consequences." National Journal of Physiology, Pharmacy and Pharmacology Online First: 13 Apr, 2024. doi:10.5455/njppp.2024.14.03137202404042024



MLA (The Modern Language Association) Style

R, Vignesh, Arun Walwekar, Vishwanath G Shettar, and Rekha Walwekar. "A prospective study of demographic, clinical profile, treatment of necrotizing fasciitis, and its consequences." National Journal of Physiology, Pharmacy and Pharmacology Online First: 13 Apr, 2024. Web. 19 Apr 2024 doi:10.5455/njppp.2024.14.03137202404042024



APA (American Psychological Association) Style

R, V., Walwekar, . A., Shettar, . V. G. & Walwekar, . R. (2024) A prospective study of demographic, clinical profile, treatment of necrotizing fasciitis, and its consequences. National Journal of Physiology, Pharmacy and Pharmacology, Online First: 13 Apr, 2024. doi:10.5455/njppp.2024.14.03137202404042024